Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy

被引:0
作者
Pierre-Jean Lamy
Pascal Pujol
Simon Thezenas
Andrew Kramar
Philippe Rouanet
Françoise Guilleux
Jean Grenier
机构
[1] Laboratoire d'Oncobiologie,Service de Biologie Cellulaire et INSERM U540
[2] Centre Hospitalo-Universitaire Arnaud de Villeneuve,Service de chirurgie
[3] Service de biostatistique,undefined
[4] CRLC Val d'Aurelle,undefined
来源
Breast Cancer Research and Treatment | 2002年 / 76卷
关键词
breast cancer; estrogen receptors; progesterone receptors; prognosis; tamoxifen;
D O I
暂无
中图分类号
学科分类号
摘要
There is now an emerging body of evidence that shows there is a relationship between the survival of breast cancer patients and the expression level of steroid receptors. The aim of this study was to determine the relationship existing between estrogen receptors (ER) and progesterone receptors (PR) cytosolic content and the prognosis of postmenopausal breast cancer women under tamoxifen therapy. Two hundred and nineteen postmenopausal patients, without neoadjuvant chemotherapy and treated postoperatively with tamoxifen for at least 2 years, were followed up in our Cancer Center. We used flexible regression modeling and log likelihood methods for determining optimum cut-off values for steroid receptors, which allows the separation of patients into significantly different categories in term of survival. For PR, 3 categories were defined (category 1: PR < 10, category 2: 10 ≤ PR < 60 and category 3: PR ≥60 fmol/mg P). Univariate analysis at 8 years indicated that significant differences in event-free survival (EFS) were found for tumor size (T) (p = 0.005), lymph node status (N) (p = 0.003), histological Scarff, Bloom and Richardson grade (p = 0.003), ER values divided into 5 categories (p = 0.02) and PR values divided into 3 categories (p = 1 · 10−5). Eight-year EFS rate for the 3 PR categories, adjusted for N, were 39, 66 and 81%, respectively. Multivariate Cox analysis indicated that only T, N and PR values were significant variables for EFS. Patients with PR values ≥60 present significantly greater EFS rates than patients with PR < 60 (p < 0.001). Our results show that the PR level in ER positive postmenopausal women is a strong prognostic marker in postmenopausal breast cancer women under tamoxifen therapy.
引用
收藏
页码:65 / 71
页数:6
相关论文
共 107 条
[1]  
Clark GM(1988)Steroid receptors and other prognostic factors in primary breast cancer Semin Oncol 15 20-25
[2]  
McGuire WL(1980)The value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 36 2884-2888
[3]  
Osborne CK(1969)Comparative binding of estrogens and its relation to estrogenic potency Steroids 13 163-178
[4]  
Yochmovitz MG(1951)Protein measurement with the Folin phenol reagent J Biol Chem 193 265-275
[5]  
Knight WA(1989)Flexible regression models with cubic splines Stat Med 8 551-561
[6]  
McGuire WL(1989)Menopausal status and cut-off levels of steroid receptors ligand binding assay in breast cancer Anticancer Res 9 173-176
[7]  
Korenman SG(1998)Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause Cancer 83 698-705
[8]  
Lowry OH(1977)Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer Cancer Res 37 4669-4671
[9]  
Roseborough N(1971)Estrogen receptors and breast carcinoma response to adrenalectomy Natl Cancer Inst Monogr 34 55-70
[10]  
Farr L(1985)Beneficial effect of tamoxifen in primary breast cancer patients with high oestrogen receptor values Lancet 1 16-18